Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Chiral Pharmaceutical Intermediate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN112300047A reveals a novel Ru-catalyzed tandem reductive amination for chiral lactams, offering high enantioselectivity and streamlined manufacturing for pharmaceutical intermediates.
Patent CN1376659A reveals a safe metal borohydride reduction system for high-purity chiral intermediates, offering significant cost and supply chain advantages.
Patent CN1328230C details asymmetric transfer hydrogenation of imines using Rh/Ru/Ir catalysts for high-purity pharmaceutical intermediates.
Novel asymmetric catalytic synthesis for chiral fluorinated building blocks. Enhances drug development efficiency and supply chain reliability for pharmaceutical intermediates.
Patent CN105112468A reveals multi-enzyme systems for chiral amine synthesis. Achieve high purity and cost reduction in pharmaceutical intermediate manufacturing with scalable biocatalysis.
Patent CN104513117B details copper-catalyzed asymmetric decarboxylation for high-purity intermediates. Offers cost reduction and scalable supply chain solutions for global pharma manufacturing.
Patent CN110467555A reveals mild chiral phosphoric acid catalysis for high-purity pharmaceutical intermediates. Enables cost reduction and supply chain reliability for global buyers.
Solve chiral drug synthesis challenges with metal-free catalysis. Achieve >99% ee, mild conditions, and scalable production for pharmaceutical intermediates. Reduce costs and supply chain risks.
Discover industrial-scale synthesis of axial chiral isopyrone-indole derivatives with 92% ee and 80% yield. Solve supply chain risks for anticancer drug development with mild reaction conditions.
Solve low enantioselectivity & high cost in chiral indole synthesis. This patent's mild, scalable method delivers >90% ee & 98% yield for anti-tumor drug intermediates. Request COA now.
Solve low yield and safety issues in chiral indole synthesis. Our CDMO expertise delivers 90-95% ee and 64-98% yield for anti-tumor drug intermediates.
Efficient, high-yield synthesis of axial chiral indole-naphthalene compounds with >95% ee. Reduce R&D costs and supply chain risks for asymmetric catalysis applications.
Solve asymmetric synthesis challenges with 98:2 enantioselectivity and 86% yield. Reduce production costs and supply chain risks for cancer drug development.
Solve high-cost, low-yield challenges in chiral indole synthesis. This patent reveals a mild, scalable method with >90% ee and 98% yield for anti-cancer drug intermediates.
Tackle high Lefamulin production costs and low yields with emerging chiral synthesis. Discover efficient, green routes for pharmaceutical intermediates. Find reliable suppliers for scalable production.
Overcome flammable borane issues in S-beta-hydroxy-gamma-butyrolactone synthesis with new BiBr3-based process. Find reliable suppliers for pharma intermediates.